Molecular cross-talk between Y5-receptor and neuropeptide Y drives liver cancer

Dietrich P, Wormser L, Fritz V, Seitz T, de Maria M, Schambony A, Kremer A, Günther C, Itzel T, Thasler WE, Teufel A, Trebicka J, Hartmann A, Neurath M, von Hörsten S, Boßerhoff AK, Hellerbrand C (2020)

Publication Language: English

Publication Type: Journal article

Publication year: 2020


Book Volume: 130

Pages Range: 2509-2526

Journal Issue: 5

DOI: 10.1172/JCI131919


Hepatocellular carcinoma (HCC) is clearly age-related and represents one of the deadliest cancer types worldwide. Due to globally increasing risk factors including metabolic disorders, the incidence rates of HCC are still rising. However, the molecular hallmarks of HCC remain poorly understood. Neuropeptide Y (NPY) and NPY-receptors represent a highly conserved, stress-activated system which is involved in diverse cancer-related hallmarks including aging and metabolic alterations, but its impact on liver cancer had been unclear. Here, we observed increased NPY5-receptor (Y5R) expression in HCC which correlated with tumor growth and survival. Furthermore, we found that its ligand NPY was secreted by peri-tumorous hepatocytes. Hepatocyte-derived NPY promoted HCC progression by Y5R-activation. Transforming growth factor beta 1 (TGFβ1) was identified as a regulator of NPY in hepatocytes and induced Y5R in invasive cancer cells. Moreover, NPY-conversion by dipeptidylpeptidase 4 (DPP4) augmented Y5R-activation and function in liver cancer. The TGFβ-NPY-Y5R-axis and DPP4 represent attractive therapeutic targets for controlling liver cancer progression.

Authors with CRIS profile

Additional Organisation(s)

Related research project(s)

Involved external institutions

How to cite


Dietrich, P., Wormser, L., Fritz, V., Seitz, T., de Maria, M., Schambony, A.,... Hellerbrand, C. (2020). Molecular cross-talk between Y5-receptor and neuropeptide Y drives liver cancer. Journal of Clinical Investigation, 130(5), 2509-2526.


Dietrich, Peter, et al. "Molecular cross-talk between Y5-receptor and neuropeptide Y drives liver cancer." Journal of Clinical Investigation 130.5 (2020): 2509-2526.

BibTeX: Download